Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) - Total Liabilities
Based on the latest financial reports, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has total liabilities worth $3.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Lakewood-Amedex Biotherapeutics Inc. Com defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Total Liabilities Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Lakewood-Amedex Biotherapeutics Inc. Com to evaluate the company's liquid asset resilience ratio.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Lakewood-Amedex Biotherapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
India | Rs1.26 Billion |
|
Wang & Lee Group, Inc. Ordinary Shares
NASDAQ:WLGS
|
USA | $5.23 Million |
|
Nusantara Inti Corpora Tbk
JK:UNIT
|
Indonesia | Rp116.65 Million |
|
Rights and Issues Investment Trust Public Limited Company
LSE:RIII
|
UK | GBX435.00K |
|
Valora Effekten Handel AG
F:VEH
|
Germany | €608.96K |
|
elexxion AG
XETRA:E8X
|
Germany | €4.57K |
|
TELES Informationstechnologien AG
XETRA:TLIK
|
Germany | €4.29 Million |
|
Advent Technologies Holdings Inc
NASDAQ:ADN
|
USA | $24.46 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Lakewood-Amedex Biotherapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lakewood-Amedex Biotherapeutics Inc. Com asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 15.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lakewood-Amedex Biotherapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the annual total liabilities of Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.45 Million | +270.08% |
| 2024-12-31 | $660.97K | -71.70% |
| 2023-12-31 | $2.34 Million | -- |
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more